Imatinib Resistance Mutation Analysis (IRMA) Test
Understanding Imatinib Resistance in CML Treatment
The Imatinib Resistance Mutation Analysis (IRMA) Test represents a breakthrough in personalized cancer care for patients with chronic myeloid leukemia (CML). This sophisticated molecular diagnostic test specifically identifies genetic mutations within the BCR-ABL kinase domain that can lead to treatment resistance, enabling oncologists to make data-driven decisions about therapeutic strategies.
What Does the IRMA Test Detect?
The IRMA Test employs advanced PCR and sequencing technologies to identify specific point mutations in the BCR-ABL gene that interfere with imatinib’s ability to effectively inhibit the abnormal tyrosine kinase activity responsible for CML progression. The test analyzes the kinase domain where mutations most commonly occur, including:
- Gatekeeper mutations (T315I)
- ATP-binding pocket mutations
- Activation loop mutations
- P-loop mutations
- Other clinically significant resistance mutations
Who Should Consider the IRMA Test?
This test is particularly important for CML patients experiencing:
- Suboptimal response to imatinib therapy
- Loss of previously achieved hematologic or cytogenetic response
- Rising BCR-ABL transcript levels during treatment
- Failure to achieve major molecular response
- Progression to accelerated or blast phase CML
- Planning for treatment modification or switch
Clinical Indications and Symptoms
Patients demonstrating signs of treatment resistance should consider the IRMA Test, including those with:
- Persistent leukocytosis despite imatinib therapy
- Recurrent splenomegaly or constitutional symptoms
- Abnormal blood counts suggesting disease progression
- Inadequate response after 3-6 months of treatment
- Previous treatment failure with imatinib
Benefits of IRMA Testing
Undergoing the Imatinib Resistance Mutation Analysis provides numerous clinical advantages:
- Personalized Treatment Planning: Identifies specific mutations to guide targeted therapy selection
- Timely Intervention: Enables early detection of resistance before clinical progression
- Optimized Therapy: Helps select appropriate second-generation TKIs based on mutation profile
- Improved Outcomes: Facilitates better disease control and long-term survival
- Cost-Effective Care: Prevents unnecessary continuation of ineffective treatments
- Enhanced Quality of Life: Reduces side effects from ineffective medications
Scientific Foundation
The IRMA Test builds upon decades of research in molecular oncology and pharmacogenomics. BCR-ABL mutations represent the primary mechanism of acquired resistance to imatinib, occurring in approximately 50-90% of resistant cases. These mutations typically affect drug binding affinity or alter the kinase conformation, rendering imatinib less effective at inhibiting the abnormal tyrosine kinase activity that drives CML progression.
Understanding Your Test Results
Your IRMA Test results will provide critical information about your treatment response:
- No Mutation Detected: Suggests other resistance mechanisms may be involved; consider dose optimization or alternative resistance evaluation
- Specific Mutation Identified: Provides guidance for selecting appropriate alternative tyrosine kinase inhibitors
- T315I Mutation: Indicates resistance to most TKIs except ponatinib; requires specialized treatment approach
- Multiple Mutations: May indicate complex resistance patterns requiring comprehensive management strategies
Clinical Interpretation Guidance
Your oncologist will interpret the results in the context of your clinical status, treatment history, and other laboratory findings. The presence of specific mutations may indicate the need for:
- Dose escalation of current therapy
- Switching to second-generation TKIs (dasatinib, nilotinib, bosutinib)
- Consideration of third-generation inhibitors for specific mutations
- Evaluation for allogeneic stem cell transplantation
- Participation in clinical trials for novel therapies
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Imatinib Resistance Mutation Analysis (IRMA) Test | $262 USD | $254 USD |
Sample Requirements and Processing
Sample Type: 4 mL (2 mL minimum) whole blood in 1 Lavender Top (EDTA) tube
Shipping Instructions: Ship refrigerated. DO NOT FREEZE
Required Documentation: Submit latest BCR-ABL Quantitative report along with sample
Turnaround Time: Sample by Monday 11 AM; Report by Saturday
Nationwide Accessibility
We have branches across all major cities in the United States, including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many more. Our extensive network ensures convenient access to this crucial diagnostic testing regardless of your location.
Why Choose Our Testing Services?
Our molecular diagnostics laboratory maintains the highest standards of accuracy and reliability. We utilize state-of-the-art sequencing technologies and maintain rigorous quality control measures to ensure precise mutation detection. Our team of molecular pathologists and genetic specialists provides comprehensive interpretation and clinical correlation.
Take Control of Your CML Treatment
Don’t let treatment uncertainty compromise your health outcomes. The IRMA Test provides the critical information needed to optimize your CML management strategy. Early detection of resistance mutations can significantly impact your treatment success and long-term prognosis.
Ready to Schedule Your Test?
Take the next step in personalized cancer care. Contact our specialists today to schedule your Imatinib Resistance Mutation Analysis and gain valuable insights into your treatment response.
Call or WhatsApp: +1(267) 388-9828
Our genetic counseling team is available to answer your questions and help you understand how this test can benefit your specific situation. Book your appointment today and move forward with confidence in your treatment journey.
